A citation-based method for searching scientific literature

Pamela Abdayem, David Planchard. Expert Opin Drug Saf 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Acquired amegakaryocytic thrombocytopenia after durvalumab administration.
Takahiro Suyama, Masao Hagihara, Naoto Kubota, Yoshiyuki Osamura, Yoko Shinka, Naoki Miyao. J Clin Exp Hematop 2021
2
100

Management of Hematologic Adverse Events Associated With Immune Checkpoint Inhibitors.
Barbara Barnes Rogers, Carolyn Zawislak, Victoria Wong. J Adv Pract Oncol 2021
1
100

Nivolumab-related severe thrombocytopenia in a patient with relapsed lung adenocarcinoma: a case report and review of the literature.
Takeo Hasegawa, Yuki Ozaki, Takuya Inoue, Yuzuru Watanabe, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Muto, Naoyuki Okabe, Mitsunori Higuchi, Yutaka Shio,[...]. J Med Case Rep 2019
10
100

Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Andrew Hantel, Brooke Gabster, Jason X Cheng, Harvey Golomb, Thomas F Gajewski. J Immunother Cancer 2018
25
100

Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review.
Jindřich Kopecký, Petronela Trojanová, Ondřej Kubeček, Otakar Kopecký. Jpn J Clin Oncol 2015
25
100

Possible atezolizumab-associated acute kidney injury and immune thrombocytopenia.
Ali Yılmaz, Cem Mirili, Mehmet Bilici, Salim Başol Tekin. J Oncol Pharm Pract 2020
3
100


Immune-related adverse events as predictors of response in cancer patients undergoing immunotherapy.
A Ezponda Casajús, M Calvo Imirizaldu, J P de Torres Tajes, A García-Baizán, E Castañón Álvarez, D Cano Rafart, I Vivas Pérez, G Bastarrika Alemañ. Radiologia (Engl Ed) 2020
4
100

Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma.
Kentaro Tokumo, Takeshi Masuda, Takahiko Miyama, Shinichiro Miura, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, Takashi Yoshida,[...]. Lung Cancer 2018
19
100



Nivolumab-Induced Thrombotic Thrombocytopenic Purpura in a Patient with Anal Squamous Cell Carcinoma: A Lesson on Hematologic Toxicity from Immunotherapy.
Mansour Gergi, Kara K Landry, Steven Ades, Maura Barry, Neil A Zakai, Diego Adrianzen Herrera. Oncologist 2020
1
100

Management of immune-related adverse events and kinetics of response with ipilimumab.
Jeffrey S Weber, Katharina C Kähler, Axel Hauschild. J Clin Oncol 2012
947
100

Immune thrombocytopenia after immune checkpoint inhibitor therapy.
Idoroenyi Amanam, Rohan Gupta, Vinod Pullarkat, Matthew Mei. Br J Haematol 2021
1
100

Eltrombopag olamine for refractory immune-related thrombocytopenia induced by pembrolizumab in a non-small cell lung cancer patient.
Munehiro Ito, Shintaro Kanda, Tatsuya Yoshida, Yusuke Okuma, Hitomi Jo, Suguru Fukuhara, Akiko Miyagi Maeshima, Yuichiro Ohe. Lung Cancer 2020
1
100

Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
J M Michot, J Lazarovici, A Tieu, S Champiat, A L Voisin, M Ebbo, B Godeau, M Michel, V Ribrag, O Lambotte. Eur J Cancer 2019
39
100

Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients.
Alessio Cortellini, Rita Chiari, Biagio Ricciuti, Giulio Metro, Fabiana Perrone, Marcello Tiseo, Melissa Bersanelli, Paola Bordi, Daniele Santini, Raffaele Giusti,[...]. Clin Lung Cancer 2019
59
100

Immune thrombocytopenia induced by nivolumab in a patient with non-small cell lung cancer.
Hidenori Mori, Chizuru Sakai, Masamichi Iwai, Yuka Sasaki, Takenobu Gomyo, Sayaka Toyoshi, Daizo Kaito, Komei Yanase, Fumitaka Ito, Junki Endo,[...]. Respir Med Case Rep 2019
10
100

Immune Thrombocytopenia Induced by Nivolumab in a Metastatic Non-Small Cell Lung Cancer Patient.
Yusuf Karakas, Deniz Yuce, Saadettin Kılıckap. Oncol Res Treat 2017
17
100


Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab.
Takanobu Jotatsu, Keishi Oda, Yudai Yamaguchi, Shingo Noguchi, Toshinori Kawanami, Takashi Kido, Minoru Satoh, Kazuhiro Yatera. Immunotherapy 2018
22
100


Pembrolizumab-induced thrombotic thrombocytopenic purpura.
Marcus Sr Dickey, Anant J Raina, Peter J Gilbar, Brendan L Wisniowski, Joel T Collins, Bhaskar Karki, Andrew Dk Nguyen. J Oncol Pharm Pract 2020
13
100

Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Nicolas Delanoy, Jean-Marie Michot, Thibault Comont, Nora Kramkimel, Julien Lazarovici, Romain Dupont, Stéphane Champiat, Claude Chahine, Caroline Robert, Charles Herbaux,[...]. Lancet Haematol 2019
94
100


PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy.
Verena Rolfes, Christian Idel, Ralph Pries, Kirstin Plötze-Martin, Jens Habermann, Timo Gemoll, Sabine Bohnet, Eicke Latz, Julika Ribbat-Idel, Bernardo S Franklin,[...]. Oncotarget 2018
21
100

Clinical significance of HLA-DRB1*0410 in Japanese patients with idiopathic thrombocytopenic purpura.
S Nomura, T Matsuzaki, Y Ozaki, M Yamaoka, C Yoshimura, K Katsura, G L Xie, H Kagawa, T Ishida, S Fukuhara. Blood 1998
67
100

Delayed thrombocytopenia as a rare but serious adverse event secondary to immune checkpoint inhibitor: a case report.
Hui Zhou, Ning Li, Huifeng Tang, Hang Chen, Xiaohui Chen, Liang Zhang, Diehong Tao. Ann Palliat Med 2021
2
100

Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial.
A S Mansfield, A Każarnowicz, N Karaseva, A Sánchez, R De Boer, Z Andric, M Reck, S Atagi, J-S Lee, M Garassino,[...]. Ann Oncol 2020
39
100

Development of thrombocytopenia is associated with improved survival in patients treated with immunotherapy.
Hussein A Assi, Adam S Asch, Michael Machiorlatti, Sara K Vesely, Sami Ibrahimi. Future Sci OA 2020
4
100

A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Mathilde Berger, Mona Amini-Adlé, Laura Crumbach, Etienne Paubelle, Stéphane Dalle. Eur J Cancer 2019
2
100

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Julie R Brahmer, Christina Lacchetti, Bryan J Schneider, Michael B Atkins, Kelly J Brassil, Jeffrey M Caterino, Ian Chau, Marc S Ernstoff, Jennifer M Gardner, Pamela Ginex,[...]. J Clin Oncol 2018
100



Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Eileen Shiuan, Kathryn E Beckermann, Alpaslan Ozgun, Ciara Kelly, Meredith McKean, Jennifer McQuade, Mary Ann Thompson, Igor Puzanov, John P Greer, Suthee Rapisuwon,[...]. J Immunother Cancer 2017
73
100

Hematologic Complications of Immune Checkpoint Inhibitors.
Elizabeth J Davis, Joe-Elie Salem, Arissa Young, Jennifer R Green, P Brent Ferrell, Kristin K Ancell, Benedicte Lebrun-Vignes, Javid J Moslehi, Douglas B Johnson. Oncologist 2019
50
100

PDCD1 and CTLA4 polymorphisms affect the susceptibility to, and clinical features of, chronic immune thrombocytopenia.
Tetsuhiro Kasamatsu, Rumi Ino, Noriyuki Takahashi, Nanami Gotoh, Yusuke Minato, Makiko Takizawa, Akihiko Yokohama, Hiroshi Handa, Takayuki Saitoh, Norifumi Tsukamoto,[...]. Br J Haematol 2018
10
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.